I think what is going on is that Zenith may have become the first priority for Don McCaffrey.  Get Zenith Epigenetics sold out (maybe to Pfizer?), leave some cash in Zenith Capital (and dividend out 90+%), which can then be used to keep RVX alive. 

Then, wait for Breakthrough Therapy designation to come through for RVX208.  Finally, sell RVX to someone like Pfizer or Eli Lilly.  My fond hope is that we are sold by June 2020.  I don't think Don wants to go to a partnership...that is pure talk, IMHO...game theory would suggest such brave talk. In reality, RVX should now be inside some bigger company like LLY or PFE.

The share price is being held back purely on the lack of news on where the funding for RVX's daily expenses is coming from.  RVX has sometimes gone to a near death situation when it comes to exchange requirements, and I am sure the market is subconsciously aware of that..and is pricing it accordingly.  But I can't see reason for that to be a good excuse anymore...the game is far too advanced, and the stakes are rising exponentially with every fresh development.